VFA
IONS icon

Values First Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Values First Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,594
Closed -$57K – 245
2023
Q1 		$57K Buy
+1,594
New +$59.9K 0.04% 184

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Values First Advisors's IONS Position: Q2 2023 in Review

Values First Advisors sold out of Ionis Pharmaceuticals (IONS) in Q2 2023, closing a stake of 1,594 shares — an estimated $57K sold.

Values First Advisors first reported a position in IONS in Q1 2023 and held it in 1 quarter. The position peaked at $57K in Q1 2023. 304 funds tracked by Wall St. Rank hold IONS as of Q2 2023.

  • Values First Advisors reported no remaining Ionis Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Values First Advisors sold 1,594 Ionis Pharmaceuticals shares in Q2 2023, an estimated $57K.
  • Values First Advisors first reported a position in Ionis Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Values First Advisors's Ionis Pharmaceuticals position peaked at $57K in Q1 2023.
  • 304 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2023.

Based on Values First Advisors's 13F filing for Q2 2023, filed 2 Aug 2023.